In8bio Inc (INAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, In8bio Inc (INAB) has a cash flow conversion efficiency ratio of -0.217x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.95 Million) by net assets ($22.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is In8bio Inc's balance sheet to measure how much of total assets are equity-financed.
In8bio Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how In8bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore In8bio Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
In8bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of In8bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Exicure Inc
NASDAQ:XCUR
|
-0.544x |
|
Rigsave S.P.A.
XETRA:H68
|
N/A |
|
GULLBERG+JANSSON AB
F:9D7
|
0.050x |
|
Inventure Growth & Securities Limited
NSE:INVENTURE
|
0.008x |
|
Globe Textiles (India) Limited
NSE:GLOBE
|
-0.089x |
|
REC Silicon ASA
OL:RECSI
|
0.174x |
|
Reliance Home Finance Limited
NSE:RHFL
|
-0.095x |
|
SaveLend Group AB
ST:YIELD
|
0.019x |
Annual Cash Flow Conversion Efficiency for In8bio Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of In8bio Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see In8bio Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.56 Million | $-12.71 Million | -0.461x | +72.34% |
| 2024-12-31 | $14.48 Million | $-24.15 Million | -1.668x | -78.21% |
| 2023-12-31 | $24.94 Million | $-23.34 Million | -0.936x | +11.79% |
| 2022-12-31 | $22.73 Million | $-24.12 Million | -1.061x | -199.92% |
| 2021-12-31 | $38.18 Million | $-13.51 Million | -0.354x | +9.13% |
| 2020-12-31 | $18.32 Million | $-7.13 Million | -0.389x | -102.81% |
| 2019-12-31 | $-346.00K | $-4.80 Million | 13.876x | +2428.66% |
| 2018-12-31 | $4.65 Million | $-2.77 Million | -0.596x | -- |
About In8bio Inc
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell… Read more